EmCyte Corp. v. Apex Biologix

CourtDistrict Court, M.D. Florida
DecidedSeptember 29, 2023
Docket2:19-cv-00769
StatusUnknown

This text of EmCyte Corp. v. Apex Biologix (EmCyte Corp. v. Apex Biologix) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
EmCyte Corp. v. Apex Biologix, (M.D. Fla. 2023).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA FORT MYERS DIVISION

EMCYTE CORP.,

Plaintiff,

v. 2:19-cv-769-JES-NPM

XLMEDICA, INC., and ANNA STAHL,

Defendants / Counterclaimants,

v.

EMCYTE CORP. and PATRICK PENNIE,

Counterclaim Defendants.

DISCOVERY ORDER This action presents a trademark-infringement suit and a tortious-interference countersuit. But so far, the action has been commandeered by discovery disputes. While neither side is entirely blameless, fault for the discovery logjams and inordinate delays lies almost exclusively with defendants Anna Stahl and her company XLMedica. Among numerous examples that could be cited, they were rather coy about and ultimately refused to give EmCyte the address of Stahl’s twin sister and business partner Angel Oliferuk (even though Oliferuk resided with Stahl, as EmCyte eventually discovered), and EmCyte had to go so far as to obtain court orders—or at least move to compel—to get Stahl, Oliferuk, and another business partner, Susie Lopez,1 to appear for depositions. Defendants’ tendency to be less than straight with the court just makes matters

worse. We were told—repeatedly—that XLMedica is nothing more than a moribund “one woman shop,” only to learn that XLMedica is in fact a robust enterprise supported by a multi-state sales force and marketing, promotion, and financial

personnel.2 We were told—repeatedly—that Defendants did not have any more documents responsive to discovery requests, only to learn that they simply didn’t look for documents where any reasonable person would (such as Lopez’s and Oliferuk’s files) or reasonably search the files of other custodians.3 And now, we

are faced with Defendants’ contumacious refusal to comply with a crystal-clear directive stated repeatedly by the court: to provide EmCyte a copy of the entire native file of XLMedica’s Quickbooks data.

We first tried to unloose this Gordian knot during a March 2021 discovery hearing, in which the court ordered Stahl to appear for her deposition, ordered XLMedica to produce the native file of its Quickbooks data, and ordered both Stahl and XLMedica to produce other documents and supplement their interrogatory

answers. (Docs. 107, 110). In October 2022—immediately after the courthouse was

1 Lopez is such a critical figure to Defendants’ enterprise that, by their own account, they would suffer “irreparable harm” if she were to discontinue working with them. See Doc. 258 at 3, 7.

2 Among other things, see generally Doc. 274.

3 Id. Especially pages 155-164, 167-170, 174-175, 207. struck by the eyewall of Hurricane Ian—the court held a status conference and disposed of a second round of discovery motions. (Docs. 228, 229, 234, 235, 237).

Among other things, the court ordered the parties to exchange detailed descriptions about the methods employed to identify and produce responsive documents, to produce certain documents, and to continue conferring about their respective

document requests; ordered XLMedica (once again) to supplement its interrogatory answers; and rejected Defendants’ request to allow them to unilaterally amend the parties’ stipulated confidentiality agreement. (Doc. 237). And because Defendants had steadfastly certified—unjustifiably and in bad faith—that they had “no

responsive documents” after deliberately using an unreasonable plan to identify, collect, and produce responsive documents, the court found EmCyte entitled to a fee-and-expense award for having to litigate this discovery violation. (Doc. 246).

But two issues remained: determining a reasonable amount for this award and deciding who should have to pay it—Defendants, their counsel, or both. So the court directed EmCyte to quantify the fees and expenses related to its sanctions motion, and it directed Defendants to appear in person for an evidentiary hearing. (Docs.

237, 246). Purported conflicts were presented about Defendants’ availability for the evidentiary hearing (Doc. 258), and thus, the court instead conducted a full-day status conference with the parties’ counsel in December 2022 to narrow the issues

in dispute and steer their discovery efforts to a conclusion. (Docs. 262, 263, 271). The record developed during the December 2022 conference confirmed Defendants’ document-production efforts were improper, and their discovery

certifications were unjustified. For example, after the October 2022 hearing, Defendants produced about 1600 pages of non-duplicative and responsive documents from the files of Lopez and Oliferuk—custodians whose files would have

been searched by any reasonable and good-faith litigant from the very beginning.4 With the sustained pattern of unreasonable intransigence in response to various discovery requests despite the multiple changes in counsel for the defense, the conference also confirmed that Defendants, rather than their counsel, should bear

the brunt of the fee award to EmCyte for having to litigate this issue. Finally, the conference confirmed that fact discovery was substantially complete. Surprisingly, the production of the native file of XLMedica’s Quickbooks data

remained at issue. Defense counsel reported that—for eventual production to EmCyte—Stahl had given the file to her prior counsel (the second of her three sets of lawyers who have represented her in this matter), but they could not confirm that it was ever furnished to EmCyte. And they resisted the production of any complete,

4 In fact, between the October 2022 and December 2022 hearings in this matter, the defendants produced an additional 4,469 pages of documents (almost double what they produced before). See Doc. 250 at 3, 5. This substantial production of documents belied not only Defendants’ discovery responses, but their representations to the court in opposition to EmCyte’s motion for sanctions. See, e.g., Doc. 152 at 12 (“EmCyte’s mere wish for more documents or suspicion that ‘there must be more’ does not change the reality that there is not more.”); id. at 14 (“Much to EmCyte’s dismay, Defendants cannot produce what they do not have.”). native-file updates going forward. But the court declined their invitation to revisit its prior ruling, rejected their suggestions that only truncated or filtered sets of data

should be provided instead, and directed them to produce the entire native file within two weeks and to continue sending a complete copy of the entire native file every month thereafter.

On the eve of the full-day status conference, Defendants filed a motion for sanctions against EmCyte concerning its document-production certifications, and this motion remains pending. (Doc. 245). In the time since the conference, Defendants have also filed a motion for a protective order concerning non-party

subpoenas that EmCyte has directed to certain financial institutions. (Doc. 281). And because Defendants continue to defy the court’s orders directing them to produce the entire native file of the Quickbooks dataset, EmCyte has filed a motion

requesting an evidentiary hearing to determine an appropriate sanction. (Doc. 279). I. Quantifying an Appropriate Expense-of-Motion Award for Defendants’ Improper Document-Production Practices

Having determined that EmCyte is entitled to a fee-and-expense award for its discovery-violation motion (Doc. 142) and that this sanction should be assessed against Defendants, rather than their counsel, we are left with determining an appropriate amount to be paid. EmCyte seeks $37,566. (Doc. 257). XLMedica and Stahl argue the award should be in the neighborhood of $3,000 - $5,000. (Doc. 269 at 19). Falling in between, the court imposes an $11,329 sanction against the defendants. The lodestar method guides the analysis for arriving at a reasonable sanction.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

ACLU of Georgia v. Miller
168 F.3d 423 (Eleventh Circuit, 1999)
Bivins v. Wrap It Up, Inc.
548 F.3d 1348 (Eleventh Circuit, 2008)
City of Burlington v. Dague
505 U.S. 557 (Supreme Court, 1992)
Campbell v. Green
112 F.2d 143 (Fifth Circuit, 1940)
United States v. Garrett
571 F.2d 1323 (Fifth Circuit, 1978)

Cite This Page — Counsel Stack

Bluebook (online)
EmCyte Corp. v. Apex Biologix, Counsel Stack Legal Research, https://law.counselstack.com/opinion/emcyte-corp-v-apex-biologix-flmd-2023.